XML 46 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Note 4 - Collaboration Revenue (Details Textual)
$ / shares in Units, ¥ in Billions
 1 Months Ended 3 Months Ended
Jun. 13, 2022
USD ($)
shares
Nov. 12, 2020
shares
Jun. 30, 2020
$ / shares
shares
Jun. 30, 2022
USD ($)
Nov. 30, 2020
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Nov. 12, 2022
$ / shares
Sep. 30, 2021
USD ($)
Sep. 30, 2021
CNY (¥)
Dec. 31, 2020
USD ($)
Revenue from Contract with Customer, Including Assessed Tax           $ 0 $ 0        
Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]                      
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value $ 3,763,000                   $ 5,267,000
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]                      
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received                 $ 108,638,000 ¥ 0.7  
Collaboration Agreement, Maximum Commercial Milestones to be Received                 62,079,000 0.4  
Revenue from Contract with Customer, Excluding Assessed Tax           0 0        
Revenues         $ 780,000 3,000          
Derivative Liability                     $ 278
Revenue from Contract with Customer, Including Assessed Tax           $ 500,000 $ 500,000        
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-1 Preferred Shares [Member]                      
Stock Issued for Transfer of Assets, Shares (in shares) | shares   9,631,941                  
Stock Issued During Period, Shares, New Issues (in shares) | shares   1,194,030                  
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]                      
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,990,000 1,990,000 1,990,000                
Shares Issued, Price Per Share (in dollars per share) | $ / shares     $ 2.5125                
Stock Issued During Period, Value, New Issues $ 5,000,000     $ 1,990,000,000              
Proceeds from Issuance or Sale of Equity       $ 5,000,000              
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | Additional Series A-2 Preferred Shares [Member]                      
Shares Issued, Price Per Share (in dollars per share) | $ / shares               $ 2.5125      
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | Maximum [Member]                      
Collaborative Arrangement, Equity Investment         $ 10,000,000            
Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member] | Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member]                      
Collaboration Agreement, Upfront Cash Payment                 $ 31,039,000 ¥ 0.2